Utah Medical Products Inc's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Utah Medical Products Inc's ROA in the second quarter of 2026?
Utah Medical Products Inc achieved a return on average assets (ROA) of 8.5 % in its second quarter of 2026, which is below Utah Medical Products Inc's average return on assets, which stands at 13.07%.

ROA fell compared to the first quarter of 2026, despite the net income growth of 3.15% from the first quarter of 2026.

However, within the Healthcare sector 110 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 695, from total ROA ranking in the first quarter of 2026 at 771.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	3.12 %	1.52 %	0 %	-5.95 %	-6.83 %
Y / Y Net Income Change	-11.88 %	-14.37 %	-11.61 %	-26.16 %	-11.73 %
Net Income (TTM) in million	10	11	11	12	13
Return On Assets (TTM)	8.5 %	8.86 %	9.25 %	9.53 %	10.13 %
UTMD's Total Ranking	# 695	# 771	# 642	# 608	# 592
Total Assets (TTM) in million	125	124	123	122	121
Seq. Total Assets Change	0.15 %	1.5 %	0.46 %	0.97 %	-1.4 %
Seq. Net Income Change	3.15 %	1.52 %	-2.51 %	-13.68 %	0.23 %

UTMD's 5 Years Annual ROA >> Back to UTMD Management Effectiveness >> Compare UTMD ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 32
Sector	# 111
Overall	# 727

Return On Assets Statistics
High	Average	Low
18.88 %	13.07 %	8.5 %
(Dec 31 2018)		(Jun 30 2026)

Financial Statements
Utah Medical Products Inc's Assets	$ 125 million	UTMD's Balance sheet
Utah Medical Products Inc's Income	$ 3 million	Quarterly UTMD's Income Statement
UTMD's Income by Division		See UTMD's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	0 %	-9.54 %	9.35 %	7.12 %	3.48 %
Total Assets in million	123	123	135	124	116
Y / Y Net Income Change	-18.65 %	-16.6 %	0.98 %	11.39 %	36.95 %
Net Income in million	11	14	17	16	15
Annual Return On Assets	9.21 %	11.32 %	12.28 %	13.3 %	12.79 %

UTMD's 5 Years Annual ROA >> Back to UTMD Management Effectiveness >> Compare UTMD ROA to its Competitors

Comment on UTMD's ROA in the fiscal year ending 2025

In the fiscal year 2025 Utah Medical Products Inc's ROA decreased compared to previous year to 9.21 %, due to deterioration of net income -18.65 % to $11.29 million, from $13.87 million a year ago, as UTMD's assets were $122.54 million.

More Return On Assets Ratios
UTMD's' Return on Assets at Yahoo Finance
Medical Equipment & Supplies Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
UTMD's Roa Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for UTMD's Competitors
Subscribers only: Roa for Utah Medical Products Inc's Suppliers
Subscribers only: Return On Assets for UTMD's Customers

You may also want to know
UTMD's Roi	UTMD's Inventory Turnover Ratio	UTMD's Growth Rates	UTMD's Dividend Comparisons
	UTMD's Profitability Ratios	UTMD's Asset Turnover Ratio	UTMD's Dividend Growth
UTMD's Roe	UTMD's Valuation Ratios	UTMD's Financial Strength Ratios	UTMD's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector	ROA
Eli Lilly And Company	21.97 %
Innoviva Inc	21.64 %
Vaxart Inc	20.85 %
Zevra Therapeutics Inc	20.39 %
Iradimed Corporation	20.36 %
Protalix Biotherapeutics inc	20.09 %
Pro dex Inc	19.87 %
Electromed Inc	19.39 %
United Therapeutics Corporation	17.98 %
Resmed Inc	17.80 %
Krystal Biotech Inc	17.65 %
Chemed Corporation	17.52 %
Zoetis Inc	17.19 %
Vertex Pharmaceuticals Inc	16.88 %
Halozyme Therapeutics Inc	16.55 %
Alnylam Pharmaceuticals Inc	15.76 %
Intuitive Surgical Inc	15.63 %
Healthcare Services Group Inc	15.21 %
Inspire Medical Systems inc	15.21 %
Dexcom Inc	14.87 %
Neurocrine Biosciences Inc	14.73 %
Entera Bio Ltd	14.60 %
Standard Biotools Inc	14.31 %
Arcutis Biotherapeutics Inc	14.23 %
Harmony Biosciences Holdings inc	14.15 %
Biolife Solutions Inc	14.09 %
Aveanna Healthcare Holdings Inc	13.82 %
West Pharmaceutical Services Inc	13.64 %
Medinotec Inc	13.38 %
Puma Biotechnology Inc	13.28 %

Date modified: 2026-09-04T10:52:04+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.